Radius Health to Present at the Canaccord Genuity 34th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 10:30 a.m. Eastern Time at the Intercontinental Hotel in Boston.

The presentation will be webcast live on the Company's website at www.radiuspharm.com. A replay of the webcast will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The company's lead development candidate is abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases. www.radiuspharm.com

CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health